Home

Johnson & Johnson (JNJ)

151.33
+0.00 (0.00%)
NYSE · Last Trade: May 19th, 5:02 AM EDT
QuoteNewsPress ReleasesChartHistoricalFAQAboutCompetitors

Detailed Quote

Previous Close151.33
Open-
Bid151.11
Ask151.53
Day's RangeN/A - N/A
52 Week Range140.68 - 169.99
Volume2,302
Market Cap397.80B
PE Ratio (TTM)-
EPS (TTM)-
Dividend & Yield4.960 (3.28%)
1 Month Average Volume7,764,826

Chart

About Johnson & Johnson (JNJ)

Johnson & Johnson is a multinational corporation engaged in the development, manufacturing, and marketing of a wide range of healthcare products. The company operates through three primary segments: pharmaceuticals, medical devices, and consumer health products. Johnson & Johnson is known for its commitment to innovation in healthcare, producing a diverse array of products that include prescription medications for various diseases, sophisticated medical devices for surgical procedures, and widely recognized consumer brands for personal care and wellness. With a focus on improving health outcomes, the company aims to address the evolving needs of patients and consumers around the world. Read More

News & Press Releases

Meet the Warren Buffett Investment That's Gained 5,502,284% and Looks Set to Soar Even Higherfool.com
Warren Buffett has had a lot of successful investments, but one in particular has crushed the stock market time and again.
Via The Motley Fool · May 18, 2025
3 Magnificent Stocks That Are Passive Income Machinesfool.com
Via The Motley Fool · May 17, 2025
US-China Trade Truce, Trump's Middle East Deals Spark Wall Street Rally: This Week In Marketsbenzinga.com
U.S. and China cut tariffs by 115 points, sparking a stock rally and improving trade outlook. Trump secures $2 trillion in Gulf deals.
Via Benzinga · May 16, 2025
Nachawati Law Group Files New Ovarian Cancer Lawsuits Against Johnson & Johnson After Latest Bankruptcy Ploy Fails
Following a third failed bankruptcy maneuver by Johnson & Johnson (NYSE: JNJ), trial lawyers with Dallas-based Nachawati Law Group have filed three new lawsuits on behalf of women who developed cancer after prolonged use of the company’s talc-based products.
By Nachawati Law Group · Via Business Wire · May 15, 2025
Why Pfizer Is Poised For A Strong Comeback: My Top Pick For 2025benzinga.com
For investors willing to look beyond the current negative sentiment, Pfizer at today's prices represents a rare buying opportunity.
Via Benzinga · May 15, 2025
Jim Cramer Says Even 'Safety' Stocks Look Risky, Warns Of 'Wild Card' In Washington And Rising Treasury Yields As Reasons To Stay Away From Sure Betsbenzinga.com
Rising bond yields and uncertain politics make 'safety' stocks less appealing, says Jim Cramer. Even Procter & Gamble and Johnson & Johnson suddenly feel shaky to the market guru.
Via Benzinga · May 15, 2025
Johnson & Johnson to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference
Johnson & Johnson (NYSE: JNJ) will participate in the Goldman Sachs 46th Annual Global Healthcare Conference on Wednesday, June 11th, 2025. Management will participate in a Fireside Chat at 3:20 p.m. Eastern Time.
By Johnson & Johnson · Via Business Wire · May 14, 2025
Sanofi To Navigate Tariff Impact With $20 Billion In Spending Through 2030benzinga.com
Sanofi plans $20 billion US investment by 2030 to expand R&D and manufacturing, aiming to boost medicine production and job creation across states.
Via Benzinga · May 14, 2025
CMS Expands Medicare Drug Price Talks To Part B Meds In 2026 Shake Upbenzinga.com
CMS draft expands drug price talks to include Medicare Part B drugs and outlines steps for future renegotiations; public comments due by June 26.
Via Benzinga · May 14, 2025
The Smartest Dividend Stocks to Buy With $5,000 Right Nowfool.com
Via The Motley Fool · May 13, 2025
Trump Unveils 'Historic And Transformative' $600 Billion Saudi Deal, Predicts Markets Will 'Go A Lot Higher'benzinga.com
President Trump unveils a $600 billion Saudi investment package into the U.S., with major deals in tech, defense, energy, and healthcare.
Via Benzinga · May 13, 2025
13 Analysts Have This To Say About Johnson & Johnsonbenzinga.com
Via Benzinga · May 13, 2025
Peering Into Johnson & Johnson's Recent Short Interestbenzinga.com
Via Benzinga · May 13, 2025
Top Biotech Halozyme Undercuts Its Breakout On Bad Medicare Newsinvestors.com
It's biggest product will be up for price negotiations under the Inflation Reduction Act much sooner than expected.
Via Investor's Business Daily · May 13, 2025
Top S&P500 movers in Monday's pre-market sessionchartmill.com
Stay updated with the S&P500 stocks that are on the move in today's pre-market session.
Via Chartmill · May 12, 2025
S&P 500, Dow Jones Pharma Stocks Boomerang As Trump Threatens Drug-Price Reforminvestors.com
It's still unclear how President Donald Trump plans to tie drug prices in the U.S. to international prices.
Via Investor's Business Daily · May 12, 2025
Mark Cuban Slams Charlie Kirk Over Drug Price Debate, Says PBMs — Not Big Pharma — Are The Real Villains: 'For Your Company...Ask Your PBM For A List Of Claims'benzinga.com
Mark Cuban, the billionaire entrepreneur, challenged Trump-supporter and political activist Charlie Kirk's stance on high drug prices, asserting that Pharmacy Benefit Managers (PBMs) are the main culprits, not Big Pharma.
Via Benzinga · May 12, 2025
Cathie Wood Says AI Innovation In Healthcare Will Be More 'Profound' Than Autonomous Taxi Networks, Humanoid Robotsbenzinga.com
Cathie Wood highlights the rising applications of AI and how it is poised to impact the health care space.
Via Benzinga · May 12, 2025
Trump's New Drug Pricing Executive Order Could Rattle Pharma Stocks, With Price Cuts Of Up To 80%: Novo Nordisk, Pfizer And J&J Fall In Premarketbenzinga.com
What Happened: On Sunday, President Donald Trump announced on Truth Social that he plans to sign what he called the "most consequential executive order" in U.S. history, aimed at lowering prescription drug prices.
Via Benzinga · May 12, 2025
Trump Says Prescription Drug Prices Set To Drop By 30% To 80% 'Almost Immediately' Thanks To 'Most Favored Nation' Plan, Mark Cuban Urges President To 'Force Transparency'benzinga.com
Trump vows to slash drug prices with new executive order, potentially dropping them by 30-80%.
Via Benzinga · May 11, 2025
Protagonist/Johnson & Johnson Partnered Drug Shows Significant Skin Clearance In Pivotal Psoriasis Studybenzinga.com
Protagonist and J&J report strong Phase 3 psoriasis data for icotrokinra and unveil potent next-gen IL-17 blocker PN-881 at SID meeting.
Via Benzinga · May 9, 2025
Johnson & Johnson’s Psoriasis Drug Meets Goal In Late Stage Study: Retail Yet To Be Impressedstocktwits.com
The company said that 66% of patients with scalp psoriasis and 77% with genital psoriasis treated with investigational oral Icotrokinra achieved site-specific clear or almost clear skin at week 16.
Via Stocktwits · May 9, 2025
Mattel Appoints Kenvue CFO Paul Ruh As Finance Chief As Toy Maker Navigates Tariff Challengesstocktwits.com
Before Kenvue and Johnson & Johnson, Ruh was at PepsiCo for 17 years.
Via Stocktwits · May 8, 2025
Are Your Health Care ETFs Safe? Trump's New Policies May Trigger Shockwaves Across Pharma Stocksbenzinga.com
Pharma ETFs closely watched as Trump's drug policies stir market volatility. Funds offer sector exposure but differ in risk levels and growth potential.
Via Benzinga · May 8, 2025
Johnson & Johnson expands efforts to champion the nursing workforce globally
Johnson & Johnson today announced the expansion of its efforts to champion the nursing workforce and improve access to quality care for communities around the world. These efforts are part of J&J CareCommunity, a new social impact platform that focuses the resources and expertise of J&J and J&J Foundation to support nurses at every step of their career journey and strengthen health systems worldwide. The expansion aims to help address the global shortfall of nurses, which will reach approximately 4.5 million by 2030, driven in part by burnout and low morale, contributing to a significant gap in care and poorer patient outcomes.
By Johnson & Johnson · Via Business Wire · May 8, 2025